All patient guidesSemua panduan pasien返回全部指南
June 18, 2026 Patient guidePanduan pasien就医指南

Hainan’s New Pharma Policy Could Make China a More Viable Option for International PatientsHainan’s New Pharma Policy Could Make China a More Viable Option for International Patients海南的新医药政策可能让中国成为国际患者更可行的选择

Hainan’s latest pharmaceutical policy is, on paper, an industrial play. Issued on May 27, 2026 by the Hainan Provincial Medical Products Administration, the Several Measures on Supporting the Localized Transformation of Imported Innovative…Hainan’s latest pharmaceutical policy is, on paper, an industrial play. Issued on May 27, 2026 by the Hainan Provincial Medical Products Administration, the Several Measures on Supporting the Localized Transformation of Imported Innovative…海南最新的医药政策,从纸面上看,是一项产业布局。由海南省药品监督管理局于2026年5月27日发布的《支持进口创新药和改良型新药本地化转化的若干措施》,旨在说服跨国药企在海南生产全球疗法,并以博鳌乐城国际医疗旅游先行区作为落地跳板。

Hainan’s latest pharmaceutical policy is, on paper, an industrial play. Issued on May 27, 2026 by the Hainan Provincial Medical Products Administration, the Several Measures on Supporting the Localized Transformation of Imported Innovative Drugs and Improved New Drugs is meant to persuade multinational drugmakers to manufacture global therapies in Hainan, using the Boao Lecheng International Medical Tourism Pilot Zone as a launchpad.

But the real story is what happens downstream.

For international patients considering China as a treatment destination, the policy could translate into earlier access to overseas-approved drugs, a better chance of lower prices over time, and more mature care infrastructure inside Lecheng. It doesn’t fundamentally rewrite the rules of medical tourism, but it does make the system around high-end treatment more functional.

What the policy actually does

At the center of the new framework is what Hainan calls a “front-zone, back-factory” model: Lecheng serves as the clinical testing ground, while Hainan’s industrial parks handle manufacturing.

The policy is built around five pillars and 11 measures:

  • Rapid clinical access: Multinational companies can bring innovative drugs that are approved overseas but not yet approved in China into Lecheng for urgent clinical use. Real-world data generated there can then be submitted to China’s National Medical Products Administration, or NMPA, to help speed up nationwide approval.
  • Localized production: Companies are encouraged to run clinical use and real-world data studies in Lecheng while building manufacturing capacity in places like Haikou’s high-tech zone. Regulators are expected to step in early and provide dedicated guidance so domestic GMP processes line up with international standards.
  • Cross-border regulatory convergence: If a Hainan factory is already listed in registration dossiers in the US, EU, or Japan, its domestic application gets priority review. Companies can also reuse foreign bioequivalence and pharmaceutical data instead of repeating full local trials.
  • Market parity: Innovative drugs made in Hainan can apply for “reference preparation” status, which puts them on equal footing with imported originator drugs for reimbursement and procurement.
  • Administrative speed: The province is promising a “one enterprise, one policy” support mechanism for factory relocation, green-channel inspection processes, and drug listing on Hainan’s procurement platform within five working days after approval.

The policy also explicitly points to alignment with the PIC/S international GMP inspection framework. In practical terms, that means factories already cleared by regulators like the FDA or EMA could face a lighter domestic audit burden.

Why this matters for international patients

The policy wasn’t written as a patient-rights reform or an immigration measure. But it still matters to foreign patients because it affects the supply, speed, and quality of drugs available inside Lecheng.

Earlier access is real, but it’s limited to Lecheng

The clearest patient benefit is faster access to global therapies inside the pilot zone.

As of January 2026, Lecheng had approved more than 552 specially permitted drugs and devices, with more than 204 already in use at Ruijin Hospital Hainan (Boao Research Hospital) alone. The mix includes oncology targeted drugs, rare-disease therapies, immunotherapies, and advanced biologics that still aren’t approved across mainland China.

By the same point, 182 authorized drugs had been used across 15 clinical departments, drawing patients from Vietnam, Greece, and other countries. The real-world data pathway has already helped 21 drugs and devices accelerate toward nationwide NMPA approval, with 3–4 later entering China’s national medical insurance catalog.

That said, the promise of “zero-lag” access comes with a major boundary: it is confined to designated institutions inside Lecheng. Patients can’t simply pick up these drugs at a retail pharmacy in Sanya, Haikou, Beijing, or elsewhere. Access requires an in-hospital assessment, informed consent, and supervised use.

Costs could come down, but not overnight

The policy’s manufacturing push creates a plausible path to lower prices, especially over the long term.

Local production cuts out import tariffs and some long-haul logistics costs. One cited case involving Simcere Pharmaceutical saw a drug’s price fall from roughly CNY 10,000 per dose to CNY 500 after local production and national insurance inclusion. Separate zero-tariff policies on certain Lecheng devices have reportedly lowered production costs by around 25%.

Still, Lecheng remains a relatively premium market. International patients in 2024 spent an average of more than CNY 12,000 per person, or about USD 1,640, which suggests the zone is still oriented toward mid-to-high-budget medical travel rather than mass-market affordability.

And insurance remains a sticking point. Foreign patients are not automatically covered by China’s public medical insurance system. Whether treatment in Lecheng is reimbursable depends on the details of a patient’s international private policy and on whether the hospital has a direct-billing arrangement with carriers such as AXA, Bupa, Cigna, or MSH. That verification needs to happen before travel, not after arrival.

Quality standards look more internationally aligned

One of the more meaningful trust signals in the new policy is its emphasis on regulatory convergence.

By aligning with PIC/S and allowing the use of overseas-grade raw materials, Hainan is trying to reassure patients that a drug manufactured locally for Lecheng use is pharmaceutically equivalent to the US, EU, or Japan version. That matters, especially for medical tourists worried that a locally produced version might not match the efficacy or safety profile of what they would receive at home.

Lecheng is also investing in the patient-services layer. The Lecheng International Medical Tourism Service Center, launched on May 29, 2026, now pulls together resources from more than 40 medical institutions. It offers foreign-language hotlines, assigns a dedicated Service Officer to each international patient, and coordinates care across institutions. The zone is also drafting unified Lecheng International Medical Tourism Service Standards to normalize training and patient experience.

There are limits here too. So-called take-home privileges remain tightly controlled. Patients may be able to carry out a limited and personally reasonable supply of specially permitted drugs for continued treatment, but that process is subject to traceability rules and the medication cannot be transferred or sold. For anyone expecting months of therapy, the exact permitted quantity and paperwork should be confirmed with the hospital in advance.

Visa-free entry helps, but only within Hainan

Hainan’s 30-day visa-free entry policy for nationals of 59 countries has made the island easier to access, and since February 2024 medical treatment has explicitly counted as an eligible travel purpose. That includes travelers from the US, UK, Canada, Australia, Japan, and most EU countries, arriving via airports in Haikou, Sanya, or Qionghai (Boao).

The catch is that Hainan functions as a separate entry zone. A visa-free stamp for Hainan does not authorize onward travel to the rest of mainland China. Patients who want to combine treatment in Lecheng with consultations in places like Shanghai or Beijing still need a standard Chinese visa.

Lecheng’s scale, by the numbers

The policy makes more sense when viewed against Lecheng’s operating footprint in early 2026:

  • Medical institutions operating: 36
  • Cumulative specially permitted drugs/devices introduced: 552+
  • Patient visits benefiting from special policies: 190,000+
  • Ruijin Hospital Hainan approved special items: 221
  • Ruijin Hospital Hainan items in active use: 204
  • Ruijin Hospital Hainan national first-use cases: 141
  • 2025 total medical tourists: 865,460, up 109.2% year over year
  • 2025 inbound international medical tourists: about 10,000 from 14 countries and regions
  • Average spend per international tourist in 2024: more than CNY 12,000

Those numbers show a zone expanding quickly, but they also underscore an important reality: international patients are still a small slice of the total volume. The foreign-patient experience is improving, but it’s still being built out in real time.

The fine print international patients shouldn’t ignore

Some of the more optimistic takes on the policy gloss over its constraints. Those limits matter.

It’s an industrial policy, not a travel-policy overhaul

The measures do not loosen visa rules beyond what already exists, change hospital admission criteria for foreigners, or broadly expand licensing options for foreign physicians. What they do is improve drug access inside Lecheng.

The benefits are highly concentrated geographically

The fast-track access to specially permitted drugs remains a Lecheng-specific privilege. Hospitals elsewhere in Hainan may eventually benefit from local manufacturing, but the headline advantage still lives inside the Boao Lecheng zone.

Rollout will be gradual

Even with a friendlier policy framework, therapies still need real-world data, factory investment, and NMPA review. Patients seeking a specific treatment in Q3 2026 should confirm that it is already on the authorized list instead of assuming the May 2026 policy has made it immediately available.

There’s no special fast lane for foreign patients

Foreign and Chinese patients are subject to the same drug-use rules inside the zone. The existence of international patient services does not mean separate prescribing rules or privileged access to therapies.

Insurance remains case by case

A drug’s presence in Lecheng does not mean an insurer will reimburse it. Direct-pay partnerships exist with some global carriers, but gaps are common, and pre-authorization is essential.

A practical checklist before you book

For patients seriously considering treatment in Hainan, the prep work matters as much as the policy itself.

  • Confirm the drug is actually available: Check the latest Lecheng special-use catalog or contact the international department of the hospital you plan to visit.
  • Verify insurance coverage: Ask your insurer or broker for pre-authorization and confirm whether the hospital supports direct billing for your plan.
  • Plan your route carefully: If you’re relying on Hainan’s visa-free entry, book a direct international flight into Haikou, Sanya, or Boao rather than transiting through another mainland Chinese city without a mainland visa.
  • Request a Service Officer in advance: The Lecheng International Medical Tourism Service Center can help coordinate foreign-language support and case management before arrival.
  • Clarify take-home medication rules: If your therapy needs continuation outside Lecheng, ask the hospital pharmacy about allowed quantities, paperwork, and customs procedures.
  • Budget beyond the drug itself: Hospital fees, nearby resort-area accommodation, companion travel, and repeat visits can all significantly affect the total cost.

The bottom line

Hainan’s May 2026 pharmaceutical policy is best understood as a supply-chain and regulatory upgrade with real, if indirect, benefits for international patients.

It does not magically remove the friction from medical tourism. It doesn’t make every cutting-edge therapy instantly available, and it doesn’t guarantee reimbursement or unlimited portability. But it does shorten the distance between global drug approval and clinical availability in China, create long-term pressure for lower prices through local manufacturing, and push Lecheng further toward internationally recognizable quality standards.

For patients looking for advanced oncology, rare-disease, or immunotherapy options that are approved in the US or EU but not yet broadly available in Asia, Lecheng is starting to look like a more credible alternative to traveling to North America or Europe. The tradeoff is that patients still need to work within the zone’s geographic limits, insurance uncertainty, and tightly managed logistics.

In that sense, the policy isn’t a magic door. It’s a structural upgrade to everything behind it. And for the right patient, at the right moment, that could make all the difference.

Hainan’s latest pharmaceutical policy is, on paper, an industrial play. Issued on May 27, 2026 by the Hainan Provincial Medical Products Administration, the Several Measures on Supporting the Localized Transformation of Imported Innovative Drugs and Improved New Drugs is meant to persuade multinational drugmakers to manufacture global therapies in Hainan, using the Boao Lecheng International Medical Tourism Pilot Zone as a launchpad.

But the real story is what happens downstream.

For international patients considering China as a treatment destination, the policy could translate into earlier access to overseas-approved drugs, a better chance of lower prices over time, and more mature care infrastructure inside Lecheng. It doesn’t fundamentally rewrite the rules of medical tourism, but it does make the system around high-end treatment more functional.

What the policy actually does

At the center of the new framework is what Hainan calls a “front-zone, back-factory” model: Lecheng serves as the clinical testing ground, while Hainan’s industrial parks handle manufacturing.

The policy is built around five pillars and 11 measures:

  • Rapid clinical access: Multinational companies can bring innovative drugs that are approved overseas but not yet approved in China into Lecheng for urgent clinical use. Real-world data generated there can then be submitted to China’s National Medical Products Administration, or NMPA, to help speed up nationwide approval.
  • Localized production: Companies are encouraged to run clinical use and real-world data studies in Lecheng while building manufacturing capacity in places like Haikou’s high-tech zone. Regulators are expected to step in early and provide dedicated guidance so domestic GMP processes line up with international standards.
  • Cross-border regulatory convergence: If a Hainan factory is already listed in registration dossiers in the US, EU, or Japan, its domestic application gets priority review. Companies can also reuse foreign bioequivalence and pharmaceutical data instead of repeating full local trials.
  • Market parity: Innovative drugs made in Hainan can apply for “reference preparation” status, which puts them on equal footing with imported originator drugs for reimbursement and procurement.
  • Administrative speed: The province is promising a “one enterprise, one policy” support mechanism for factory relocation, green-channel inspection processes, and drug listing on Hainan’s procurement platform within five working days after approval.

The policy also explicitly points to alignment with the PIC/S international GMP inspection framework. In practical terms, that means factories already cleared by regulators like the FDA or EMA could face a lighter domestic audit burden.

Why this matters for international patients

The policy wasn’t written as a patient-rights reform or an immigration measure. But it still matters to foreign patients because it affects the supply, speed, and quality of drugs available inside Lecheng.

Earlier access is real, but it’s limited to Lecheng

The clearest patient benefit is faster access to global therapies inside the pilot zone.

As of January 2026, Lecheng had approved more than 552 specially permitted drugs and devices, with more than 204 already in use at Ruijin Hospital Hainan (Boao Research Hospital) alone. The mix includes oncology targeted drugs, rare-disease therapies, immunotherapies, and advanced biologics that still aren’t approved across mainland China.

By the same point, 182 authorized drugs had been used across 15 clinical departments, drawing patients from Vietnam, Greece, and other countries. The real-world data pathway has already helped 21 drugs and devices accelerate toward nationwide NMPA approval, with 3–4 later entering China’s national medical insurance catalog.

That said, the promise of “zero-lag” access comes with a major boundary: it is confined to designated institutions inside Lecheng. Patients can’t simply pick up these drugs at a retail pharmacy in Sanya, Haikou, Beijing, or elsewhere. Access requires an in-hospital assessment, informed consent, and supervised use.

Costs could come down, but not overnight

The policy’s manufacturing push creates a plausible path to lower prices, especially over the long term.

Local production cuts out import tariffs and some long-haul logistics costs. One cited case involving Simcere Pharmaceutical saw a drug’s price fall from roughly CNY 10,000 per dose to CNY 500 after local production and national insurance inclusion. Separate zero-tariff policies on certain Lecheng devices have reportedly lowered production costs by around 25%.

Still, Lecheng remains a relatively premium market. International patients in 2024 spent an average of more than CNY 12,000 per person, or about USD 1,640, which suggests the zone is still oriented toward mid-to-high-budget medical travel rather than mass-market affordability.

And insurance remains a sticking point. Foreign patients are not automatically covered by China’s public medical insurance system. Whether treatment in Lecheng is reimbursable depends on the details of a patient’s international private policy and on whether the hospital has a direct-billing arrangement with carriers such as AXA, Bupa, Cigna, or MSH. That verification needs to happen before travel, not after arrival.

Quality standards look more internationally aligned

One of the more meaningful trust signals in the new policy is its emphasis on regulatory convergence.

By aligning with PIC/S and allowing the use of overseas-grade raw materials, Hainan is trying to reassure patients that a drug manufactured locally for Lecheng use is pharmaceutically equivalent to the US, EU, or Japan version. That matters, especially for medical tourists worried that a locally produced version might not match the efficacy or safety profile of what they would receive at home.

Lecheng is also investing in the patient-services layer. The Lecheng International Medical Tourism Service Center, launched on May 29, 2026, now pulls together resources from more than 40 medical institutions. It offers foreign-language hotlines, assigns a dedicated Service Officer to each international patient, and coordinates care across institutions. The zone is also drafting unified Lecheng International Medical Tourism Service Standards to normalize training and patient experience.

There are limits here too. So-called take-home privileges remain tightly controlled. Patients may be able to carry out a limited and personally reasonable supply of specially permitted drugs for continued treatment, but that process is subject to traceability rules and the medication cannot be transferred or sold. For anyone expecting months of therapy, the exact permitted quantity and paperwork should be confirmed with the hospital in advance.

Visa-free entry helps, but only within Hainan

Hainan’s 30-day visa-free entry policy for nationals of 59 countries has made the island easier to access, and since February 2024 medical treatment has explicitly counted as an eligible travel purpose. That includes travelers from the US, UK, Canada, Australia, Japan, and most EU countries, arriving via airports in Haikou, Sanya, or Qionghai (Boao).

The catch is that Hainan functions as a separate entry zone. A visa-free stamp for Hainan does not authorize onward travel to the rest of mainland China. Patients who want to combine treatment in Lecheng with consultations in places like Shanghai or Beijing still need a standard Chinese visa.

Lecheng’s scale, by the numbers

The policy makes more sense when viewed against Lecheng’s operating footprint in early 2026:

  • Medical institutions operating: 36
  • Cumulative specially permitted drugs/devices introduced: 552+
  • Patient visits benefiting from special policies: 190,000+
  • Ruijin Hospital Hainan approved special items: 221
  • Ruijin Hospital Hainan items in active use: 204
  • Ruijin Hospital Hainan national first-use cases: 141
  • 2025 total medical tourists: 865,460, up 109.2% year over year
  • 2025 inbound international medical tourists: about 10,000 from 14 countries and regions
  • Average spend per international tourist in 2024: more than CNY 12,000

Those numbers show a zone expanding quickly, but they also underscore an important reality: international patients are still a small slice of the total volume. The foreign-patient experience is improving, but it’s still being built out in real time.

The fine print international patients shouldn’t ignore

Some of the more optimistic takes on the policy gloss over its constraints. Those limits matter.

It’s an industrial policy, not a travel-policy overhaul

The measures do not loosen visa rules beyond what already exists, change hospital admission criteria for foreigners, or broadly expand licensing options for foreign physicians. What they do is improve drug access inside Lecheng.

The benefits are highly concentrated geographically

The fast-track access to specially permitted drugs remains a Lecheng-specific privilege. Hospitals elsewhere in Hainan may eventually benefit from local manufacturing, but the headline advantage still lives inside the Boao Lecheng zone.

Rollout will be gradual

Even with a friendlier policy framework, therapies still need real-world data, factory investment, and NMPA review. Patients seeking a specific treatment in Q3 2026 should confirm that it is already on the authorized list instead of assuming the May 2026 policy has made it immediately available.

There’s no special fast lane for foreign patients

Foreign and Chinese patients are subject to the same drug-use rules inside the zone. The existence of international patient services does not mean separate prescribing rules or privileged access to therapies.

Insurance remains case by case

A drug’s presence in Lecheng does not mean an insurer will reimburse it. Direct-pay partnerships exist with some global carriers, but gaps are common, and pre-authorization is essential.

A practical checklist before you book

For patients seriously considering treatment in Hainan, the prep work matters as much as the policy itself.

  • Confirm the drug is actually available: Check the latest Lecheng special-use catalog or contact the international department of the hospital you plan to visit.
  • Verify insurance coverage: Ask your insurer or broker for pre-authorization and confirm whether the hospital supports direct billing for your plan.
  • Plan your route carefully: If you’re relying on Hainan’s visa-free entry, book a direct international flight into Haikou, Sanya, or Boao rather than transiting through another mainland Chinese city without a mainland visa.
  • Request a Service Officer in advance: The Lecheng International Medical Tourism Service Center can help coordinate foreign-language support and case management before arrival.
  • Clarify take-home medication rules: If your therapy needs continuation outside Lecheng, ask the hospital pharmacy about allowed quantities, paperwork, and customs procedures.
  • Budget beyond the drug itself: Hospital fees, nearby resort-area accommodation, companion travel, and repeat visits can all significantly affect the total cost.

The bottom line

Hainan’s May 2026 pharmaceutical policy is best understood as a supply-chain and regulatory upgrade with real, if indirect, benefits for international patients.

It does not magically remove the friction from medical tourism. It doesn’t make every cutting-edge therapy instantly available, and it doesn’t guarantee reimbursement or unlimited portability. But it does shorten the distance between global drug approval and clinical availability in China, create long-term pressure for lower prices through local manufacturing, and push Lecheng further toward internationally recognizable quality standards.

For patients looking for advanced oncology, rare-disease, or immunotherapy options that are approved in the US or EU but not yet broadly available in Asia, Lecheng is starting to look like a more credible alternative to traveling to North America or Europe. The tradeoff is that patients still need to work within the zone’s geographic limits, insurance uncertainty, and tightly managed logistics.

In that sense, the policy isn’t a magic door. It’s a structural upgrade to everything behind it. And for the right patient, at the right moment, that could make all the difference.

海南最新的医药政策,从纸面上看,是一项产业布局。由海南省药品监督管理局于2026年5月27日发布的《支持进口创新药和改良型新药本地化转化的若干措施》,旨在说服跨国药企在海南生产全球疗法,并以博鳌乐城国际医疗旅游先行区作为落地跳板。

但真正的故事,在于下游会发生什么。

对于将中国视为治疗目的地的国际患者而言,这项政策可能意味着更早获得海外已批准药物的机会、更有希望随着时间推移迎来更低价格,以及乐城内部更成熟的医疗服务基础设施。它并没有从根本上改写医疗旅游的规则,但确实让高端治疗周边的整个系统更好用了。

这项政策实际上做了什么

新框架的核心,是海南所称的“前区后厂”模式:乐城作为临床试验与应用场景,海南产业园区则承担生产制造。

该政策围绕五大支柱和11项措施展开:

  • 临床快速准入: 跨国公司可将已在海外获批但尚未在中国获批的创新药引入乐城,用于急需临床使用。在那里产生的真实世界数据,随后可提交给中国国家药品监督管理局(NMPA),以帮助加快全国范围内的审批。
  • 本地化生产: 鼓励企业在乐城开展临床使用和真实世界数据研究的同时,在海口高新区等地建设生产能力。监管部门预计将提前介入并提供专项指导,使国内GMP流程与国际标准接轨。
  • 跨境监管趋同: 如果海南工厂已被列入美国、欧盟或日本的注册申报资料,其国内申报将获得优先审评。企业还可以复用境外生物等效性和药学数据,而不是重复开展完整的本地试验。
  • 市场同等待遇: 在海南生产的创新药可申请“参比制剂”地位,这使其在医保和采购方面可与进口原研药处于同等地位。
  • 行政提速: 该省承诺对工厂迁建提供“一企一策”支持机制、检查流程绿色通道,并在获批后五个工作日内将药品纳入海南采购平台。

政策还明确提出与PIC/S国际GMP检查框架对接。实际而言,这意味着已经通过FDA或EMA等监管机构审查的工厂,国内审计负担可能更轻。

为什么这对国际患者很重要

这项政策并不是作为患者权利改革或移民措施来制定的。但它仍然与外国患者相关,因为它影响乐城内部药品供应、可及速度和质量。

更早获得治疗是真实的,但仅限于乐城

对患者而言,最明确的好处,是在先行区内更快获得全球疗法。

截至2026年1月,乐城已批准超过552种特别许可药品和器械,仅瑞金海南医院(博鳌研究型医院)一家就已有超过204种投入使用。其中包括肿瘤靶向药、罕见病疗法、免疫疗法以及中国大陆范围内仍未获批的先进生物制剂。

截至同一时间点,已有182种获授权药品在15个临床科室中使用,吸引了来自越南、希腊等国家的患者。真实世界数据路径已经帮助21种药品和器械加速迈向全国NMPA审批,其中有3至4种后来进入了中国国家医保目录。

不过,“零时差”准入的承诺也有一个重要边界:它仅限于乐城内指定机构。患者不能简单地在三亚、海口、北京或其他地方的零售药房购买这些药物。获得用药需要院内评估、知情同意以及监督下使用。

成本可能下降,但不会一夜之间发生

这项政策推动制造的方向,为降低价格创造了一条可信路径,尤其是从长期看。

本地生产减少了进口关税和部分长距离物流成本。一个被引用的案例涉及先声药业,某药品在本地生产并纳入国家医保后,价格从每剂约人民币10,000元降至500元。另有报道称,针对乐城部分器械的零关税政策已将生产成本降低约25%。

尽管如此,乐城仍是一个相对高端的市场。2024年,国际患者人均花费超过人民币12,000元,约合1,640美元,这表明该区域仍然更面向中高预算的医疗旅行,而非大众化可负担市场。

而保险仍是一个症结。外国患者不会自动纳入中国公共医疗保险体系。乐城治疗是否可报销,取决于患者国际商业保险保单的具体条款,以及医院是否与AXA、Bupa、Cigna或MSH等保险机构建立直付安排。这项核验需要在出行前完成,而不是到达后再处理。

质量标准看起来与国际更加接轨

新政策中更有意义的信任信号之一,是其对监管趋同的强调。

通过与PIC/S接轨,并允许使用境外等级的原材料,海南正试图让患者相信:为乐城使用而在本地生产的药物,在药学上与美国、欧盟或日本版本等效。这一点很重要,尤其是对那些担心本地生产版本在疗效或安全性上无法匹配本国用药的医疗游客而言。

乐城也在投入患者服务层建设。于2026年5月29日启动的乐城国际医疗旅游服务中心,现已整合40多家医疗机构资源。它提供外语热线,为每位国际患者配备专属Service Officer,并协调跨机构医疗服务。该区域还正在起草统一的《乐城国际医疗旅游服务标准》,以规范培训和患者体验。

这里也存在限制。所谓的带药离院权限仍受到严格控制。患者或许可以携带数量有限且个人合理使用范围内的特别许可药品,以便继续治疗,但这一过程受可追溯规则约束,药品不得转让或出售。对于预期需要数月治疗的人来说,具体允许携带的数量及所需文件应提前向医院确认。

免签入境有帮助,但仅限于海南省内

海南对59个国家公民实行的30天免签入境政策,使该岛更易抵达;自2024年2月起,医疗治疗已被明确纳入符合条件的旅行目的。这包括来自美国、英国、加拿大、澳大利亚、日本以及大多数欧盟国家的旅客,可经海口、三亚或琼海(博鳌)机场入境。

问题在于,海南作为一个独立入境区域运作。海南免签入境章并不授权继续前往中国大陆其他地区。希望将乐城治疗与上海或北京等地会诊结合的患者,仍然需要标准中国签证。

用数字看乐城的规模

结合乐城在2026年初的运营体量,这项政策会更容易理解:

  • 运营中的医疗机构: 36家
  • 累计引进特别许可药品/器械: 552+
  • 受惠于特殊政策的就诊人次: 190,000+
  • 瑞金海南医院获批特别项目: 221项
  • 瑞金海南医院正在使用的项目: 204项
  • 瑞金海南医院全国首用案例: 141例
  • 2025年医疗旅游总人数: 865,460人次,同比增长109.2%
  • 2025年入境国际医疗游客: 约10,000人,来自14个国家和地区
  • 2024年国际游客人均花费: 超过人民币12,000元

这些数字显示该区域正在快速扩张,但也凸显了一个重要现实:国际患者在总量中仍只占很小一部分。外国患者的体验正在改善,但这一体系仍在实时建设中。

国际患者不应忽视的细则

一些对该政策较为乐观的解读,淡化了它的约束条件。而这些限制很重要。

这是产业政策,不是旅行政策的大改造

这些措施并未在现有基础上进一步放宽签证规则,也未改变外国人住院准入标准,或普遍扩大外国医生的执业许可选项。它们真正做的是改善乐城内部的药品可及性。

利益在地理上高度集中

对特别许可药品的快速通道准入,仍然是乐城特有的优势。海南其他医院未来或许最终会受益于本地制造,但最核心的优势仍然存在于博鳌乐城区域内部。

落地将是渐进的

即便政策框架更友好,相关疗法仍需要真实世界数据、工厂投资以及NMPA审评。计划在2026年第三季度寻求特定治疗的患者,应确认该疗法是否已列入授权清单,而不是假设2026年5月的政策已使其立即可得。

外国患者并没有特殊快速通道

外国患者和中国患者在该区域内适用相同的用药规则。存在国际患者服务,并不意味着有单独的处方规则或优先获得疗法的权利。

保险仍需个案判断

某种药物出现在乐城,并不意味着保险公司一定会报销。部分全球保险机构已建立直付合作,但保障缺口很常见,事先授权至关重要。

预订前的实用清单

对于认真考虑赴海南治疗的患者来说,准备工作与政策本身同样重要。

  • 确认药物确实可用: 查阅最新的乐城特许使用目录,或联系你计划前往医院的国际部。
  • 核实保险覆盖: 向你的保险公司或经纪人申请事先授权,并确认医院是否支持你所持保险计划的直付。
  • 谨慎规划路线: 如果你依赖海南免签入境,请预订直飞海口、三亚或博鳌的国际航班,而不要在没有中国大陆签证的情况下经由中国大陆其他城市中转。
  • 提前申请Service Officer: 乐城国际医疗旅游服务中心可在抵达前协助安排外语支持和病例管理。
  • 明确带药离院规则: 如果你的治疗需要在乐城之外继续进行,向医院药房咨询允许携带的数量、所需文件及海关手续。
  • 预算不要只算药费: 医院费用、附近度假区住宿、陪同人员出行以及复诊,都可能显著影响总成本。

核心结论

理解海南2026年5月医药政策的最佳方式,是将其视为一次供应链与监管体系升级;这种升级会给国际患者带来真实但间接的好处。

它并不会神奇地消除医疗旅游中的摩擦。它不会让每一种前沿疗法立刻变得可用,也不保证报销或无限制携带使用。但它确实缩短了全球药物获批与其在中国临床可及之间的距离,通过本地制造对更低价格形成长期压力,并推动乐城进一步接近国际可识别的质量标准。

对于正在寻找已在美国或欧盟获批、但尚未在亚洲广泛可及的先进肿瘤治疗、罕见病或免疫治疗方案的患者来说,乐城开始看起来像是一个比前往北美或欧洲更可信的替代选择。权衡之处在于,患者仍然需要在该园区的地域限制、保险不确定性以及严格管理的流程安排内进行操作。

从这个意义上说,这项政策并不是一扇神奇之门。它是对其背后整套体系的结构性升级。而对于合适的患者,在合适的时机,这可能会带来决定性的不同。

WhatsApp